MSKCC
Welcome,         Profile    Billing    Logout  
 29 Trials 
45 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
O'Reilly, Eileen
PROTACT, NCT01676259: A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer

Recruiting
2
80
US, RoW
siG12D-LODER, Gemcitabine+nab-Paclitaxel, Chemotherapy, Folfirinox
Silenseed Ltd
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
10/22
08/23
NCT01585805: Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Checkmark ASCO-GI 2015
Jan 2015 - Jan 2015: ASCO-GI 2015
Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Checkmark ASCO-2013
More
Active, not recruiting
2
107
Canada, US, RoW
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Gemcitabine Hydrochloride, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Veliparib, ABT-888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
12/24
12/24
NCT05630183: A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer

Recruiting
2
78
US
Botensilimab, AGEN1181, Gemcitabine, Nab-paclitaxel
Agenus Inc.
Metastatic Pancreatic Ductal Adenocarcinoma
12/24
12/24
NCT05851924: A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting
2
60
US
NALIRIFOX, AD-XRT and Capecitabine
Memorial Sloan Kettering Cancer Center, Ipsen, Pancreatic Cancer Research Fund
Pancreatic Ductal Adenocarcinoma
05/26
05/26
PRESERVE-001, NCT04140526: Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Recruiting
1/2
733
US, RoW
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody made by OncoC4, Inc., Pembrolizumab, Keytruda, MK3475, Docetaxel, Taxotere, Docefrez
OncoC4, Inc., National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
06/26
12/27
DurvaRad, NCT03245541: Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer

Active, not recruiting
1/2
18
US
Durvalumab, Medi 4736, Stereotactic Ablative Body Radiotherapy (SABR)
Memorial Sloan Kettering Cancer Center, AstraZeneca, Cedars-Sinai Medical Center
Pancreatic Adenocarcinoma
09/24
09/24
NCT05642962: Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting
1/2
40
US
Pertzye, Pancrelipase
Memorial Sloan Kettering Cancer Center
Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Carcinoma, Pancreatic Carcinoma, Pancreatic Carcinoma Metastatic, Pancreatic Carcinoma Non-resectable, Pancreatic Cancer, Pancreatic Cancer Non-resectable, Pancreatic Cancer Stage IV, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
11/24
11/24
AMPLIFY-7P, NCT05726864: A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Recruiting
1/2
156
US
ELI-002 7P
Elicio Therapeutics
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12A, KRAS G12C, KRAS G12S, KRAS G13D, NRAS G12D, NRAS G12R, NRAS G12V, NRAS G12C, NRAS G12S
11/26
11/26
AMPLIFY-201, NCT04853017: A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Active, not recruiting
1
25
US
ELI-002 2P
Elicio Therapeutics
Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma
01/23
03/26
MV-0715-CP-001.01, NCT02672917: Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

Recruiting
1
264
US
MVT-5873, HuMab-5B1, modified FOLFIRINOX (mFOLFIRINOX), gemcitabine + nab-paclitaxel
BioNTech Research & Development, Inc.
Pancreatic Cancer
08/24
10/26
ARC-8, NCT04104672: A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

Recruiting
1
195
US
AB680, Zimberelimab, AB122, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar
Arcus Biosciences, Inc.
Advanced Pancreatic Cancer
05/27
05/27
REVOLUTION, NCT04787991: Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Active, not recruiting
1
45
US
Nivolumab (Cohort A), Opdivo, Ipilimumab (Cohort A, B and C), Yervoy, Hydroxychloroquine (HCQ) (Cohort B), Plaquenil, Nab-paclitaxel (nP) (Cohort A, B and C), Abraxane, Gemcitabine (gem) (Cohort A, B and C), Gemzar, NG350A (Cohort C)
Cancer Insight, LLC, Bristol-Myers Squibb, Cancer Research Institute, New York City, Akamis Bio
Metastatic Pancreatic Adenocarcinoma
10/24
01/25
NCT05484011: A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Terminated
1
5
US
odetiglucan, Imprime, BTH-1677, Imprime PGG, CDX-1140
HiberCell, Inc., Celldex Therapeutics
Metastatic Pancreatic Adenocarcinoma
03/24
03/24
Eastham, James A
NCT00430183: Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Active, not recruiting
3
788
Canada, US
docetaxel, LHRH agonist, leuprolide acetate OR, goserelin acetate, surgery
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Eastern Cooperative Oncology Group, NCIC Clinical Trials Group, Southwest Oncology Group
Prostate Cancer
10/18
10/30
NCT05946603: IS-002 in Prostate Cancer

Recruiting
2
60
US
Administration of IS-002, Firefly fluorescent imaging, robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissection, RARP
Intuitive Surgical
Prostate Cancer
04/25
04/26
NCT03067051: Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System

Recruiting
1/2
66
Europe, Canada, US
Verteporfin, Visudyne, SpectraCure P18 System
SpectraCure AB
Recurrent Prostate Cancer
07/24
12/24
PRESERVE, NCT04972097: Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue

Active, not recruiting
N/A
121
US
Irreversible Electroporation, The NanoKnife System
Angiodynamics, Inc.
Prostate Cancer
07/24
07/24
Tap, William
MOTION, NCT05059262: Study of Vimseltinib for Tenosynovial Giant Cell Tumor

Active, not recruiting
3
120
Europe, Canada, US, RoW
vimseltinib, DCC-3014, Placebo
Deciphera Pharmaceuticals LLC
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse, Tenosynovial Giant Cell Tumor, Localized
08/23
07/26
NCT04438824: Palbociclib and INCMGA00012 in People With Advanced Liposarcoma

Active, not recruiting
2
42
US
INCMGA00012, Palbociclib
Memorial Sloan Kettering Cancer Center, Incyte Corporation
Well-differentiated/Dedifferentiated Liposarcoma
06/25
06/25
NCT05515575: A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA

Active, not recruiting
2
8
US
Niraparib
Memorial Sloan Kettering Cancer Center, GlaxoSmithKline
Sarcoma,Soft Tissue, Sarcoma Uterus
08/26
08/26
NCT05886634: A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma

Recruiting
2
25
US
Etrumadenant, Zimberelimab
Memorial Sloan Kettering Cancer Center
Dedifferentiated Liposarcoma, Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Recurrent Dedifferentiated Liposarcoma, Unresectable Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma
05/27
05/27
DCC-3014-01-001, NCT03069469: Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

Active, not recruiting
1/2
120
Europe, Canada, US, RoW
Vimseltinib, DCC-3014
Deciphera Pharmaceuticals LLC
Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Tenosynovial Giant Cell Tumor, Diffuse
07/26
08/28
CFT8634-1101, NCT05355753: A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors

Terminated
1/2
50
US
CFT8634
C4 Therapeutics, Inc.
Synovial Sarcoma, Soft Tissue Sarcoma
12/23
12/23
ALS-6000-101, NCT04969835: A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

Recruiting
1
80
Europe, US
AVA6000
Avacta Life Sciences Ltd
Pancreatic Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Cancer of Unknown Primary Site, Ovarian Cancer, Breast Cancer, Soft Tissue Sarcoma, Bladder Cancer, Oesophageal Cancer, Prostate Cancer, Biliary Tract Cancer
05/23
06/23
Contact, Use Central
NCT03684018 / 2018-003430-33: Two Dose Levels of Privigen in Pediatric CIDP

Recruiting
4
30
US
IgPro10, Privigen
CSL Behring
Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12/29
12/29
NCT04167514: Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705)

Active, not recruiting
3
136
US
Alpha-1 antitrypsin (AAT), Alpha-1 proteinase inhibitor (A1-P1), Placebo
CSL Behring, Blood and Marrow Transplant Clinical Trials Network, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI)
Graft Versus Host Disease (GVHD)
05/24
05/24
RECLAIIM, NCT04044690 / 2018-003171-35: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

Active, not recruiting
3
126
Europe, Japan, US, RoW
human immunoglobulin G, IgPro20, Hizentra, Placebo
CSL Behring, CSL Behring LLC, 1020 First Avenue, King of Prussia, PA 19406
Dermatomyositis
06/24
11/27
NCT05819775: CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

Recruiting
3
20
Europe, Canada, US, RoW
CSL312, Garadacimab
CSL Behring
Hereditary Angioedema (HAE)
11/26
11/26
IMAGINE, NCT03744910 / 2018-003682-34: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

Terminated
3
194
Europe, Canada, US, RoW
Clazakizumab, Physiologic saline solution
CSL Behring, ICON Clinical Research
Antibody-mediated Rejection
04/24
04/24
NCT06003387: Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

Recruiting
3
35
Canada, US, RoW
CSL222 (AAV5-hFIXco-Padua), Etranacogene dezaparvovec
CSL Behring
Hemophilia B
10/28
10/28
MODULAATE, NCT03805789: The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

Recruiting
2/3
310
Europe, Japan, US, RoW
Alpha-1 antitrypsin (AAT), Alpha-1 proteinase inhibitor, Placebo
CSL Behring
Acute-graft-versus-host Disease
09/25
03/27
NCT05485961: Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

Enrolling by invitation
2/3
2310
Europe, Canada, US, RoW
CSL300, Clazakizumab, Placebo
CSL Behring
Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease
12/28
12/28
NCT01294020 / 2010-020925-42: Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®

Active, not recruiting
2
81
Europe, RoW
Tacrolimus, Prograf, FK506, Tacrolimus prolonged release, FK506E, MR4, Advagraf, tacrolimus modified release, Astagraf XL, Graceptor, Prograf XL
Astellas Pharma Europe Ltd.
Intestine Transplantation, Kidney Transplantation, Lung Transplantation, Liver Transplantation, Heart Transplantation
10/15
05/26
STARBORN-1, NCT05871970: Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age

Recruiting
2
38
US
TARA-002
Protara Therapeutics
Lymphatic Malformation
12/25
05/26
ADVANCED-2, NCT05951179: Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Recruiting
2
127
US, RoW
TARA-002
Protara Therapeutics
Non-muscle Invasive Bladder Cancer
05/30
08/30
NCT04446000: Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects

Terminated
1
52
Europe
CSL730, Recombinant trivalent human IgG1 Fc multimer, Placebo
CSL Behring
Immune Complex-mediated Autoimmune Diseases
03/23
03/23
NCT05653713: Effects of CSL324 in the Lung After Segmental Challenge

Completed
1
40
Europe
CSL324, Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody (mAb), Placebo
CSL Behring
Healthy Volunteers
07/23
07/23
NCT04082754: A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers

Completed
1
78
Europe
Human beta common receptor antagonist monoclonal antibody, CSL311, Placebo
CSL Behring
Asthma
11/23
11/23
ADVANCED-1, NCT05085990: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Recruiting
1
12
US
TARA-002
Protara Therapeutics
Non-muscle Invasive Bladder Cancer
06/24
08/24
ADVANCED-1, NCT05085977: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)

Recruiting
1
18
Europe, US, RoW
TARA-002
Protara Therapeutics
Non-muscle Invasive Bladder Cancer
06/24
07/24
NCT05937581: First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

Recruiting
1
60
RoW
CSL040, Placebo
CSL Behring
Complement Deficiencies
03/25
03/25
THRIVE-1, NCT05011370: Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition

Completed
N/A
80
Europe, US
Protara Therapeutics
Intestinal Failure-associated Liver Disease
06/23
06/23
IX-TEND 4001, NCT06008938: An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B

Recruiting
N/A
500
US
HEMGENIX, Etranacogene dezaparvovec, Factor IX (FIX)
CSL Behring
Hemophilia B
08/43
08/43
Ponce, Doris M
NCT05996627: Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

Recruiting
2
82
US
Belumosudil, KD 025, KD-025, KD025, Rho-associated Coiled-coil Kinase 2 Inhibitor KD025, ROCK-II Inhibitor KD025, ROCK2 Inhibitor KD025, SLx 2119, SLx-2119, SLx2119, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Electronic Health Record Review, Placebo Administration
Fred Hutchinson Cancer Center, Sanofi
Chronic Graft Versus Host Disease
05/27
12/27
SER-155-001, NCT04995653: A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT

Active, not recruiting
1
60
US
Vancomycin Pre-Treatment, Vancomycin Placebo, SER-155, SER-155 Placebo
Seres Therapeutics, Inc., Memorial Sloan Kettering Cancer Center
Allogeneic Hematopoietic Stem Cell Transplantation
07/24
10/24

Download Options